CuraGen reports encouraging preliminary data from Phase II melanoma trial
Approximately 36 patients were enrolled into this Phase II open-label, multi-center trial that is evaluating the efficacy and safety of CR011-vcMMAE 1.88mg/kg administered intravenously once every three weeks.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.